Fig. 4From: Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide studyLS mean (SE) change from baseline (left panel) and treatment difference (right panel, exenatide twice daily − glimepiride) in HDL-cholesterol (a) and triglycerides (b) in randomized patients. BID twice daily, HDL high-density lipoprotein, LS least-squares, SE standard errorBack to article page